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Ciprofibrate is a drug indicated in cases of hypertriglyceridemia and mixed hyperlipidemia, but no 
monographs are available in official compendia for the analysis of this substance in tablets. The objective 
of this work was to develop and validate a spectrophotometric method for routine analysis of ciprofibrate 
in tablets. In this study, commercial and standard ciprofibrate were used, as well as placebo in absolute 
ethanol, analyzed by UV spectrophotometer. All tests followed the rules of Resolution RE-899, 2003. The 
results showed that the developed and validated method offers low cost, easy implementation, precision 
and accuracy, and may be included in the routine of quality control laboratories.
Uniterms: Ciprofibrate/analysis. Spectrophotometric method/medicines analysis. Medicines/quality 
control.
O ciprofibrato é um fármaco indicado em casos de hipertrigliceridemia e hiperlipidemia mista, mas não 
há monografias em compêndios oficiais para a análise desta substância em comprimidos. O objetivo deste 
trabalho é desenvolver e validar um método espectrofotométrico para análise de rotina de ciprofibrato 
em comprimidos. Neste estudo foram empregados ciprofibrato comercial, padrão e placebo em etanol 
absoluto, analisadas por espectrofotometria UV. Todos os testes seguiram as regras da Resolução RE-
899, 2003. Os resultados mostraram que o método desenvolvido e validado apresenta baixo custo, fácil 
implementação, precisão e exatidão e pode ser incluído em rotina de laboratórios de controle de qualidade.
Unitermos: Ciprofibrato/análise. Método espectrofotométrico/análise de medicamentos. Medicamentos/
controle de qualidade.
INTRODUCTION
Dyslipidemia is a chronic degenerative disease 
characterized by abnormal levels of lipids in the blood 
(Molly, Brunzel, 2004) which affects a large proportion 
of the population in different ways according to ethnicity, 
socioeconomic status and other factors (Bertolami et al., 
1993; Eizerik, Manfroi, 2008; Souza et al., 2003).
In 1998, it was found that 38% of men and 42% of 
women in the Brazilian population had total cholesterol 
levels above 200 mg/dL (DBD, 2007), and a high inci-
dence was also found in other countries including India 
and the United States of America (Davidson, Yannicelli, 
2004). Dyslipidemia is one of the factors predisposing pa-
tients to a number of diseases such as atherosclerosis (Luo 
et al., 2009) and cardiovascular problems (Lotufo, 1996).
Fibrates are a group of drugs derived from fibric acid 
(Xavier, 2005), referred to as drugs of choice for cases of 
hypertriglyceridemia as an adjuvant of statins (Schultz, 
2006) and for conditions including mixed dyslipidemia 
in patients with type-2 diabetes mellitus (DBD, 2007; 
Xavier, 2005), especially for patients resistant or intolerant 
to statins (Abourbih, 2009).
Ciprofibrate is chemically known as 2-[4-(2,2-di-
chlorocyclopropyl) phenoxy]-2-methylpropanoic acid 
(Figure 1), having a molecular formula C13H14Cl2O3 and 
molecular weight of 289.2 (Merck Index, 2001). It is a 
white crystalline or lightly yellowish powder, with a melt-
G.N.L Nascimento, D.L. Rosa, H. Nishijo, T.A. Aversi-Ferreira24
ing point of about 115.0 °C that is practically insoluble in 
water, freely soluble in anhydrous ethanol, and soluble in 
toluene (BP, 2008). 
In Brazil, ciprofibrate is marketed as Oroxadin 
(Sanifi-Aventis), Lipless (Biolab Sanus) and Ciprolip 
(Uci-Farma), all containing 100 mg per tablet in their 
presentation for oral administration.
According to Xavier (2005), fibrates are absorbed 
through the gastrointestinal tract, and glucuronidated 
compounds by the liver, and are excreted by the kidneys, 
peaking at between 2 and 8 h. Fibrates have an elimination 
half-life of between 2 and 80 h depending on the doses 
used, and act through the stimulation of nuclear recep-
tors activated by the proliferation of alpha-peroxisomes, 
leading to increased production and action of lipoprotein 
lipase, reduction of apolipoprotein CIII; decrease in the 
synthesis of VLDL and increase in HDL-c levels.
The concern about the quality of drugs sold increases 
every year (La Roca et al., 2007), not only in commercial 
terms, but also legal and ethical aspects, since the health of 
patients depends on the quality and effectiveness of these 
drugs (Linsbinski et al., 2008; Ribani et al., 2004). In this 
regard, various regulatory agencies around the world are 
demanding validation methods for the registration of new 
drugs to ensure the quality of the drugs marketed (Brasil, 
2003; Grillo et al., 2009; ICH, 1996; Santana et al., 2007; 
Valentini et al., 2004).
There is a great interest in developing rapid and 
efficient analytical methods that provide precise and ac-
curate parameters for the quantitative analysis of drugs, 
important for routine analysis during quality control and 
development of new drug forms (Ruela et al., 2009), with 
spectrophotometric analysis being the most likely candidate.
To date, no validated methods are available in offi-
cial compendia for the analysis of ciprofibrate tablets. This 
fact, together with the importance of this drug in the tre-
atment of a chronic disease that affects millions of people 
around the world, justified the conducting of a validation 
test for this drug.
The objective of this study was to develop and va-
lidate a spectrophotometric method for routine analysis 
of quality control of ciprofibrate tablets, to be used by 
industry and pharmacies.
MATERIAL AND METHODS
Equipment and reagents
The following devices were used in this study: UV 
/ Vis spectrophotometer label Agilent model G1103A, ad-
justed for detection at 233nm, using a quartz cuvette with 
an optical path of 1.0 cm, and UV/HPLC grade methanol, 
labels JTBaker and Tedia.
Samples
Commercial Ciprofibrate samples of 100mg/cp 
and its CRS ciprofibrate placebo (Chemical Reference 
Substances), previously standardized with the power of 
99.8%, were used.
Preparation of solutions
Standard Solution
To reach the adopted working concentration of 
0.01 mg/mL, the equivalent of 50.0 mg of CRS ciprofibrate 
was weighed and transferred to a volumetric flask of 50.0 mL, 
dissolved, and this volume completed with UV/HPLC 
grade methanol. From this solution, 1.0 mL was transferred 
to a volumetric flask of 100.0 mL, completed to volume with 
UV/HPLC grade methanol, and then homogenized.
Sample Solution
The average weight of  20 tablets of commercial 
sample was determined for the ciprofibrate solution sam-
ple. Once sprayed, the equivalent of 100.0 mg of ciprofi-
brate (equivalent to an average weight) was weighed and 
transferred to volumetric flask of 100.0 mL, dissolved, and 
the volume completed with methanol. The solution was 
filtered through filter paper for the retention of insoluble 
particles, and 1.0 mL was then transferred to a volume-
tric flask of 100.0 mL, filled with methanol, and then 
homogenized, in order to obtain the theoretical working 
concentration of 0.01 mg/mL.
Method validation
The validation process was performed according to 
the present guidelines contained in Resolution RE-899 of 
29 May 2003 (Brasil, 2003).
Specificity/selectivity
Commercial ciprofibrate sample solution, stan-
dard and placebo sample at the working concentration 
FIGURE 1 - Chemical structure of ciprofibrate.
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(0.01 mg/mL) were determined through analysis, using 
UV/HPLC grade methanol as the diluent.
Linearity
A standard calibration curve was constructed by 
reading, in duplicate, 5 standard solutions at concentra-
tions corresponding to 60%, 80%, 100%, 120% and 140% 
compared to the theoretical value of the working concen-
tration adopted, with values 0.006 mg/mL, 0.008 mg/mL, 
0.01 mg/mL, 0.012 mg/mL and 0.014 mg/mL, to verify the 
correspondence between absorbance and the concentra-
tions of solutions, expressed by the correlation coefficient 
obtained by the least squares method.
Precision
Precision was evaluated through the repeatability 
and intermediate precision methods. Repeatability was 
determined by preparation, under the same conditions, of 
6 analytical solutions of the sample at working concentra-
tion, by two different analysts. Intermediate accuracy was 
assessed in the same manner, on different days by different 
analysts. Relative standard deviation (RSD) of up to 5% 
was considered as acceptable, according to resolution 
899/2003 (Brasil, 2003).
Accuracy
Accuracy was assessed based on the degree of 
recovery, as percentage of placebo solutions fortified 
with known amounts of CRS ciprofibrate, in triplicate, at 
concentrations of 80%, 100% and 120% of the working 
concentration.
Robustness
The variation among solvent manufacturers was 
evaluated with sample and standard solutions at working 
concentration (0.01 mg/mL), with two different solvent 
brands (A and B), concomitant with the stability time of 
sample and standard solutions, by making periodic readings 
at 0, 2, 4, 6, 8, 10, 12, 15, 20 and 24 h of standard and sample 
solutions at working concentration (0.01 mg/mL). 
RESULTS
Specificity/selectivity
The method used was specific and selective for 
ciprofibrate through comparative analysis of placebo, 
standard and samples, prepared under the same conditions. 
There was no significant interference from other compo-
nents (placebo) at a wavelength of 233nm (Figure 2).
Linearity
The correlation coefficient (r) of the calibration 
curve was 0.99, according to RE 899/2003 (Brasil, 2003) 
minimum acceptable criterion (Figure 3).
Precision
Considering data obtained from the six analytical 
solutions prepared, the method demonstrated repeatability 
with a relative standard deviation (RSD%) of up to 2.09% 
among samples prepared on the same day under the same 
conditions, within the maximum permitted by applicable 
law of 5% RE 899/2003 (Brasil, 2003). The method also 
showed intermediate precision with RSD% of 1.86% 
among results of six analytical solutions prepared by two 
different analysts on different days.
FIGURE 2 - UV spectra of standard solution (0.01 mg/mL) of 
ciprofibrate (A) and placebo solution (B) in absolute methanol.
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Accuracy
The results for accuracy, at concentrations of 80%, 
100% and 120%, showed a mean recovery percentage of 
between 99.47% and 100.84% (Table I), compared to the 
ideal recovery of 98.0 to 102.0%.
Robustness
For the same sample, both standard solution and ci-
profibrate sample solutions analyzed using different solvent 
brands (methanol), A and B, revealed significant variations 
in the robustness test results (Table II and Table III).
The stability of analytical standard and sample so-
lutions after 2, 4, 6, 8, 10, 12, 15, 20 and 24 hours from 
the initial analysis was also evaluated. The ciprofibrate 
sample and standard solutions seemed to be stable for 24 
hours after the initial analysis, and a maximum variation 
of 1.78% in 6 hours was found (Table IV and Table V).
Statics analysis of linearity
The correlation coefficient (r) for linearity was ac-
cording to RE 899/2003 (Brasil, 2003), established at 0.99 
as a minimum criterion. Therefore, statistical analysis of 
linearity can be done to verify the robustness of this figure 
(Figure 4, Table VI). From the statistical data seen in Table 
VI, it is possible to affirm that these data present strong 
linearity (Figure 4, Table VI).
FIGURE 3 - Calibration of CRS ciprofibrate through absorption 
spectrophotometry in the UV region at 233nm.
TABLE I - Results of recovery percentage of CRS ciprofibrate in placebo at 80, 100 and 120%, in triplicate at wavelength of 233 nm
80% 100% 120%
Absorbance Conc. (%) Absorbance Conc. (%) Absorbance Conc. (%)
Average 0.3718 80.68 0.4605 99.92 0.5501 119.37
S 0.00211 0.46 0.00307 0.67 0.00438 0.95
R.S.D.% 0.56884 0.57 0.66628 0.67 0.79536 0.80
% Recovery -------- 100.84 -------- 99.92 -------- 99.47
* where S is the standard deviation, and RSD% is the relative standard deviation in %
TABLE II - Results for robustness test using ciprofibrate standard 
solution (0.01 mg/mL), varying the absolute methanol supplier
Label Absorbance % Variation 
Reagent 1 - Methanol - A 0.45816 0.00000
Reagent 2 - Methanol - B 0.45860 0.09610
TABLE III - Results for robustness test using ciprofibrate sample 
solution (0.01 mg/mL), varying the absolute methanol supplier
Label Absorbance % Variation
Reagent 1 - Methanol - A 0.45639 0.00000
Reagent 2 - Methanol - B 0.45400 -0.52259
TABLE IV - Results for stability test for ciprofibrate standard 
solution (0.01 mg/mL), varying solution preparation time
Analysis Timetable 
(hours after preparation)
Absorbance Variation (%) 
Initial Analysis 0.45947 0.00
2 hours 0.45836 -0.24
4 hours 0.45885 -0.13
6 hours 0.46277 0.72
8 hours 0.45741 -0.45
10 hours 0.46142 0.42
12 hours 0.45531 -0.91
15 hours 0.45411 -1.17
20 hours 0.45874 -0.16
24 hours 0.46061 0.25
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DISCUSSION
Methods to determine the content of drugs should 
never fail because, according to Honda and Magalhães 
(2001), possible failures may lead to erroneous decisions 
subsequently being taken based on these results. 
The selectivity and specific features of the proposed 
method is the primary principle of a high-accuracy proce-
dure, as demonstrated for the method in this study, since 
no significant interference was observed from other com-
ponents (placebo) at a wavelength of 233 nm (Figure 2).
In Figure 2a, for λ = 233 nm, the absorbance is 
approximately 0.45 AU, with coordinates located at the 
peak of a typical curve obtained in spectroscopy, while 
in Figure 2b, for λ = 233 nm, the absorbance is less than 
0.01, with coordinates located on a decreasing curve after 
the methanol absorbance peak. Based on these results, it 
was confirmed that the method to determine ciprofibrate 
content in tablets via spectrophotometer is both specific 
and selective.
The linearity of a method must be obtained by the 
correlation coefficient (r) of the calibration curve. Ac-
cording to RE 899/2003 (Brasil, 2003), the minimum 
acceptable criterion is 0.99,a level verified by statistical 
analysis (Figure 4, Table VI). According to Pimentel and 
Barros Neto (1996), the least squares method is widely 
used to verify the proximity of points obtained in relation 
to the standard line, since it provides unbiased results with 
minimum variance. 
Figure 3 shows the value of R = 0.99978 for the equa-
tion y = 45.62x + 0006 in the calibration curve of the CRS 
ciprofibrate through absorption spectrophotometry in the 
TABLE V - Results for stability test for ciprofibrate solution 
sample (0.01 mg/mL), varying solution preparation time
Analysis Timetable 
(hours after preparation)
Absorbance Variation (%) 
Initial Analysis 0.45608 0.00
2 hours 0.45623 0.03
4 hours 0.46051 0.97
6 hours 0.46418 1.78
8 hours 0.45604 -0.01
10 hours 0.45385 -0.49
12 hours 0.45589 -0.04
15 hours 0.46024 0.91
20 hours 0.45433 -0.38
24 hours 0.45656 0.11
FIGURE 4 – Linear regression graph of percentage of samples 
and absorbance.
TABLE VI – Regression analysis of percentage of samples and absorbance
Regression Statistics
R
R-square
R-square adjusted 
S
0.9995
0.999
0.9989
0.0043
Absorbance=0.0059 + 0.0046 x samples (%)
ANOVA d.f. SS MS F p-level
Regression 1 0.3329 0.3329 17.973.5309 0
Residual 18 0.0003 0.0000
Total 19 0.3332
Coefficients Standard error LCL UCL State
Intercept 0.0059 0.0035 -0.0015 0.0133 1.6645
Samples (%) 0.0046 0.0000 0.0045 0.0046 134.0654
T (5%) 2.1009
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UV region at 233nm. According to Braga and Poppi (2004) 
and to findings of the present analysis, it can be concluded 
that the linear model efficiently fits the data obtained. 
The degree of accuracy of a method is demonstrated 
by the correlation among measurements made for the same 
homogeneous sample under repeatability conditions, pre-
pared on the same day under the same conditions, and by 
different analysts (Braga, Poppi, 2004).
For the spectrophotometric determination method 
used in this work, the repeatability assessment had a 
maximum standard deviation of 2.09% for samples (6) 
prepared on the same day. This value lies within the limits 
allowed under current legislation (Brasil, 2003), stipulat-
ing that this value should not exceed 5%, while intermedi-
ate precision evaluation should have a maximum standard 
deviation of 1.86% for samples (6) analyzed by different 
analysts. Therefore, the method to determine ciprofibrate 
content is highly accurate under the conditions of this 
experiment. 
Moreover, a method must be exact. The RE 
899/2003 (Brasil, 2003) stipulates that the ideal recov-
ery degree for concentrations of 80%, 100% and 120% 
should range from a minimum of 98.0% to a maximum 
of 102.0%. The data in Table I show a recovery degree for 
these concentrations of between a minimum of 99.47% 
and maximum of 100.84% (Table I). In statistical terms, 
the data obtained in the present study are consistent and 
within the limits required by law.
In statistical terms, the least squares estimator is the 
minimum linear variance of the response variable (Pimen-
tel, Barros Neto, 1996), and therefore the values obtained 
for the detection and quantification method were within 
the parameters of safety for the linearity of data.
The results obtained by quantification of the analyti-
cal solution of the same sample, analyzed with different 
brands (methanol), A and B, revealed significant variations 
in the results, indicating high and satisfactory robustness 
of the method for small variations (Table II and Table III).
Regarding the stability of standard and sample 
analytical solutions, a maximum variation of 1.78% was 
detected in 6 hours, thus not exceeding the maximum ac-
ceptable limit adopted of 2% according to RE 899/2003 
(Brasil, 2003) (Table IV and Table 5). 
CONCLUSIONS
The method to determine ciprofibrate content in 
tablets through spectrophotometry in the ultraviolet region 
was validated according to resolution 899/2003. The re-
sults showed the method to be simple, inexpensive, easy 
to apply, precise and accurate for the determination of 
ciprofibrate. Moreover, the method provides the reliability 
required for an analytical method, and also the practicality 
required for the routine of quality control laboratories.
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